Please try another search
Nexvet Biopharma public limited company, develops and commercialises species-specific biologics. Its product candidates include Ranevetmab, a monoclonal antibody (mAb) that targets and inhibits the function of nerve growth factor (NGF) for the control of pain associated with osteoarthritis in dogs, and Frunevetmab, a mAb that targets NGF inhibitors for the control of pain associated with degenerative joint disease, including osteoarthritis in cats. In addition, it has a research and development collaboration with Zenoaq for applying PETization technology to convert mAb candidates into species-specific candidates in the areas of immuno-oncology, inflammation, and allergy. The company is based in Tullamore, Ireland. As of July 31, 2017, Nexvet Biopharma Public Limited Company operates as a subsidiary of Zoetis Inc.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review